Compare SoFi Technologies Inc (SOFI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs Viatris Inc — how do they compare? SoFi Technologies Inc trades at $17.64 (market cap $21.82B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: SoFi Technologies Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.83% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| SOFI | VTRS | |
|---|---|---|
Market Cap | $21.82B | $19.79B |
Sector | Financials | Health |
52-Week High | $32.21 | $17.39 |
52-Week Low | $15.15 | $8.74 |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoFi Technologies (SOFI) trades at $17.64, up 2.08% today, amid a bearish technical signal but strong recent earnings beats. The stock is near its consensus price target low of $17.00, with revenue growth accelerating to $3.61 billion in 2025 and a net income margin of 13.32%. Cash flow trends show heavy reliance on financing activities, while assets have grown to $36.25 billion as of 2024. Recent news highlights upcoming Q2 2026 earnings on July 29, with management guiding for 30% top-line growth.
The outlook for SOFI hinges on sustained revenue expansion and profitability improvements, but risks include negative operating cash flows and competitive pressures. Analyst sentiment is mixed with a 33.33% buy rating, suggesting cautious optimism if execution meets guidance. The stock presents a potential opportunity if Q2 earnings beat expectations, yet volatility remains high given its fintech exposure and macroeconomic sensitivity.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
